Lunit, a medical software company, agreed to acquire Volpara Health Technologies, a health technology software for breast cancer, for $193m. "Lunit's interest in acquiring Volpara is a strong testament to the high quality of our products, our significant US market presence, and the hard work of our employees. Working together, Lunit and Volpara would have the opportunity to develop products that very few companies are in a position to do. This is expected to put us at the forefront of cancer technology and position us as a global leader in our field," Teri Thomas, Volpara CEO and Managing Director.